Blue Ash Therapeutics, LLC (BAT) is a privately funded company, formed in December 2008 in Cincinnati to bring a promising cardiovascular drug – azimilide - to market. BAT acquired the license for global development of azimilide dihydrochloride from Warner Chilcott in January 2010. After reactivating the azimilide IND, BAT formed a Cincinnati-based clinical and regulatory development team that met with the FDA and gained agreement, via the Special Protocol Assessment (SPA) process, for the design and sizing of a single Phase III trial as the final efficacy study needed for marketing approval. In April 2011 the azimilide license and global development rights were purchased from BAT by Forest Labs, Inc. who will assume responsibility for the Phase III development program.

Through an asset purchase agreement, Forest was assigned the license agreement between Warner Chilcott Company and BAT, providing for worldwide rights to azimilide, and its future development and commercialization.

Azimilide is an oral once-daily cardiac antiarrhythmic drug, originally developed by Procter and Gamble Pharmaceuticals. It is in late Phase III clinical testing for use in patients whose life-threatening ventricular arrhythmias require an implantable cardioverter-defibrillator (ICD). The drug was acquired from Procter and Gamble by Warner Chilcott in late 2009, and was licensed to BAT in 2010.